Literature DB >> 1596693

Inhibition of neuropeptide Y-induced potentiation of noradrenaline-induced vasoconstriction by PP56 (D-myo-inositol 1,2,6-tris-phosphate).

M Adamsson1, B Fallgren, L Edvinsson.   

Abstract

1. Although neuropeptide Y (NPY) is a potent vasoconstrictor in many vascular beds, nanomolar concentrations of this peptide potentiate the noradrenaline-induced contractions in rabbit gastroepiploic and femoral arteries, and guinea-pig mesenteric and uterine arteries. 2. The potentiating effect of NPY on noradrenaline-induced contraction was present in endothelium-denuded femoral arteries. 3. The potentiating effect of NPY on noradrenaline-induced contraction was antagonized by PP56 (D-myo-inositol 1,2,6-trisphosphate) in low concentrations (down to 0.1 nM). This antagonistic effect was observed in all four types of vessels studied. Contractions induced by noradrenaline, histamine, endothelin-1 and potassium were not altered by PP56 in concentrations upto 1 microM in femoral artery of rabbit. 4. We provide evidence that a non-peptide (PP56) can selectively antagonize NPY-induced effects in rabbit and guinea-pig peripheral arteries without affecting the vasoconstrictor response to noradrenaline.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1596693      PMCID: PMC1908591          DOI: 10.1111/j.1476-5381.1992.tb14216.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

1.  Adenosine and neuropeptide Y enhance alpha 1-adrenoceptor-induced accumulation of inositol phosphates and attenuate forskolin-induced accumulation of cyclic AMP in rat vas deferens.

Authors:  J Häggblad; B B Fredholm
Journal:  Neurosci Lett       Date:  1987-11-23       Impact factor: 3.046

2.  Neuropeptide Y modulates adrenergic neurotransmission by an endothelium dependent mechanism.

Authors:  R N Daly; J P Hieble
Journal:  Eur J Pharmacol       Date:  1987-06-26       Impact factor: 4.432

3.  Neuropeptide Y is a potent inhibitor of cyclic AMP accumulation in feline cerebral blood vessels.

Authors:  B B Fredholm; I Jansen; L Edvinsson
Journal:  Acta Physiol Scand       Date:  1985-07

4.  Co-existence of neuropeptides and differential inhibition of vasodilator responses by neuropeptide Y in guinea pig uterine arteries.

Authors:  B Fallgren; E Ekblad; L Edvinsson
Journal:  Neurosci Lett       Date:  1989-05-22       Impact factor: 3.046

5.  Mechanisms underlying pre- and postjunctional effects of neuropeptide Y in sympathetic vascular control.

Authors:  J Pernow; A Saria; J M Lundberg
Journal:  Acta Physiol Scand       Date:  1986-02

6.  Occurrence and extracellular actions of inositol pentakis- and hexakisphosphate in mammalian brain.

Authors:  M Vallejo; T Jackson; S Lightman; M R Hanley
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

7.  Neuropeptide Y antagonistic properties of D-myo-inositol-1.2.6-trisphosphate in guinea pig basilar arteries.

Authors:  L Edvinsson; M Adamsson; I Jansen
Journal:  Neuropeptides       Date:  1990-10       Impact factor: 3.286

8.  Characterization of adrenoceptor mechanisms in isolated guinea-pig uterine arteries.

Authors:  B Fallgren; L Edvinsson
Journal:  Eur J Pharmacol       Date:  1986-11-19       Impact factor: 4.432

9.  Coronary artery infusion of neuropeptide Y in patients with angina pectoris.

Authors:  J G Clarke; G J Davies; R Kerwin; D Hackett; S Larkin; D Dawbarn; Y Lee; S R Bloom; M Yacoub; A Maseri
Journal:  Lancet       Date:  1987-05-09       Impact factor: 79.321

10.  Neuropeptide Y: cerebrovascular innervation and vasomotor effects in the cat.

Authors:  L Edvinsson; P Emson; J McCulloch; K Tatemoto; R Uddman
Journal:  Neurosci Lett       Date:  1983-12-23       Impact factor: 3.046

View more
  1 in total

1.  Involvement of nitric oxide in the regional haemodynamic effects of perindoprilat and captopril in hypovolaemic Brattleboro rats.

Authors:  S M Gardiner; T Bennett
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.